1Yang W,Lu J,Wang J,et al.Prevalence of diabetes among men and women in China[J].N Eng J Med,2010,362:1090-1101.
2Holman RR,Paul SK,Bethel MA,et al.10-year follow-up of intensive glucose control in type 2 diabetes[J].N Eegl J Med,2010,362:1090-1101.
3Neumiller JJ.Differential chemistry (structure),machanismof antion,and pharmacology of GLP-1 peceptoragonists and DPP-4 inhibitors[J].J AM Pharm Assoc,2009,49 (Suppl):16-29.
4Ahrén B,Schweizer A,Dejager S,et al.Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans[J].Diabetes Obes Metab,2011,13:775-783.
5Pratley RE,Schweizer A,Rosenstock J,et al.Robust improvements in fasting and prandial measures of B-cell function with vidagliptin in drug-native patients:analysis of pooled vidagliptin monotherapy database[J].Diabetes Obes Metab,2008,10:931-938.
6Tanp P,Yin H,Smith T,et al.Disposition of LAF237 in rats and huma-ns[J].Drug Metab Rev,2002,34(Suppl):147.
7Villhanuer Brinkman JA,Naderi GB,et al.I-[(3-hydro-Xy-1-adamanyI) amino]acet-yI]-2-cyano-(S)-pyrrolidine ; a potent,selective,and orally bi-oavaiable dipeptidy1 peptidase Ⅳ inhibitor with antihyper glycemic pro-perties[J].J Med Chem,2003,46 (13):2774-2789.
8Ahren B,Foley JE,Bosi E.Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin[J].Diabetes Obes metab,2011,13:193-203.
9Pi-Sunyer FX,Schweizer A,Mills D,et al.Efficacy and tolerability of vildagliptin monotherapy in drug-naive patient with type 2 diabetes[J].Diabetes Res Clin pract,2007,76 (1):132-138.
10Mari A,Scherbaum WA,Nilsson PM,et al.Characterization of the influence of vildagliptin on model-assessed bata-cell function in patients with type 2diabetes and mild hyperglycemia[J].J Clin Endocrinol Metab,2008,97:103-109.
